肠道来源富甘油三酯脂蛋白对接受他汀治疗的2型糖尿病患者动脉粥样硬化性心血管疾病残余风险的贡献
本研究对11例接受生活方式咨询和稳定剂量二甲双胍治疗的超重/肥胖2型糖尿病患者与11名按年龄、BMI和性别频数匹配的对照者进行二次分析,使用稳定同位素示踪剂评估标准高脂餐后ApoB-48和ApoB-100脂蛋白动力学。结果显示2型糖尿病患者餐后乳糜微粒TG和ApoB-48反应约高两倍,总ApoB-48生成高25%,乳糜微粒向VLDL转化低约40%,直接清除高5.6倍,ApoB-48 VLDL颗粒在循环中停留时间延长五倍。作者认为肠道来源ApoB-48脂蛋白代谢异常可能解释他汀治疗后的心血管疾病残余风险,并可能成为干预靶点。
要点
- 2型糖尿病患者餐后乳糜微粒TG和ApoB-48反应较对照约高两倍。
- 2型糖尿病患者总ApoB-48生成较对照高25%。
- 2型糖尿病患者ApoB-48 VLDL颗粒循环停留时间较对照延长五倍。
核心结论
- 接受他汀治疗的2型糖尿病患者肠道来源含ApoB-48脂蛋白代谢异常可能有助于解释心血管疾病残余风险,并可能成为合适的干预靶点。
研究设计与样本
- 对来自早期临床研究的11例接受生活方式咨询和稳定剂量二甲双胍治疗的超重/肥胖2型糖尿病患者与11名按年龄、BMI和性别频数匹配的对照者进行二次分析,两组研究期间接受相似他汀方案。
- 使用稳定同位素示踪剂测定标准高脂餐后乳糜微粒和VLDL中ApoB-48、VLDL/IDL/LDL中ApoB-100以及VLDL中TG的动力学。
主要发现
- 空腹血脂谱两组间无显著差异。
- 与对照相比,2型糖尿病患者乳糜微粒TG和ApoB-48对高脂餐的反应约高两倍,VLDL1和VLDL2密度范围内ApoB-48颗粒增量高两倍(均p<0.05)。
- 2型糖尿病患者总ApoB-48生成较对照高25%(556±57 vs 446±57 mg/day;p<0.001)。
- 2型糖尿病患者乳糜微粒向VLDL转化(分数转移率)较对照低约40%(35±25 vs 82±58 pools/day;p=0.034),乳糜微粒直接清除较对照高5.6倍(5.6±2.2 vs 1.0±1.8 pools/day;p<0.001)。
- 餐后期间2型糖尿病患者ApoB-48颗粒占VLDL比例较对照高(44% vs 25%),且这些ApoB-48 VLDL颗粒在循环中停留时间延长五倍(p<0.01);VLDL中ApoB-100和TG动力学、LDL ApoB-100生成、池大小和清除率两组间无差异;2型糖尿病患者IDL ApoB-100池较对照高,归因于VLDL2转化增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: This study explored the hypothesis that significant abnormalities in the metabolism of intestinally derived lipoproteins are present in individuals with type 2 diabetes on statin therapy. These abnormalities may contribute to residual CVD risk. METHODS: To investigate the kinetics of ApoB-48- and ApoB-100-containing lipoproteins, we performed a secondary analysis of 11 overweight/obese individuals with type 2 diabetes who were treated with lifestyle counselling and on a stable dose of metformin who were from an earlier clinical study, and compared these with 11 control participants frequency-matched for age, BMI and sex. Participants in both groups were on a similar statin regimen during the study. Stable isotope tracers were used to determine the kinetics of the following in response to a standard fat-rich meal: (1) apolipoprotein (Apo)B-48 in chylomicrons and VLDL; (2) ApoB-100 in VLDL, intermediate-density lipoprotein (IDL) and LDL; and (3) triglyceride (TG) in VLDL. RESULTS: The fasting lipid profile did not differ significantly between the two groups. Compared with control participants, in individuals with type 2 diabetes, chylomicron TG and ApoB-48 levels exhibited an approximately twofold higher response to the fat-rich meal, and a twofold higher increment was observed in ApoB-48 particles in the VLDL1 and VLDL2 density ranges (all p < 0.05). Again comparing control participants with individuals with type 2 diabetes, in the latter, total ApoB-48 production was 25% higher (556 ± 57 vs 446 ± 57 mg/day; p < 0.001), conversion (fractional transfer rate) of chylomicrons to VLDL was around 40% lower (35 ± 25 vs 82 ± 58 pools/day; p=0.034) and direct clearance of chylomicrons was 5.6-fold higher (5.6 ± 2.2 vs 1.0 ± 1.8 pools/day; p < 0.001). During the postprandial period, ApoB-48 particles accounted for a higher proportion of total VLDL in individuals with type 2 diabetes (44%) compared with control participants (25%), and these ApoB-48 VLDL particles exhibited a fivefold longer residence time in the circulation (p < 0.01). No between-group differences were seen in the kinetics of ApoB-100 and TG in VLDL, or in LDL ApoB-100 production, pool size and clearance rate. As compared with control participants, the IDL ApoB-100 pool in individuals with type 2 diabetes was higher due to increased conversion from VLDL2. CONCLUSIONS/INTERPRETATION: Abnormalities in the metabolism of intestinally derived ApoB-48-containing lipoproteins in individuals with type 2 diabetes on statins may help to explain the residual risk of CVD and may be suitable targets for interventions. TRIAL REGISTRATION: ClinicalTrials.gov NCT02948777.
引用
- Taskinen MR, Matikainen N, Björnson E, et al. Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy. Diabetologia. 2023. PMID: 37775612. doi:10.1007/s00125-023-06008-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。